Current status and future prospects of chimeric antigen receptor-T cell therapy in lymphoma research: A bibliometric analysis

References

• Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. doi:10.1038/s41408-021-00459-7.
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024–16. doi:10.1073/pnas.86.24.10024.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor (CAR) design. Cancer Discov. 2013;3(4):388–98. doi:10.1158/2159-8290.CD-12-0548.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3(1):35–45. doi:10.1038/nrc971.
   PubMed Web of Science ®Google Scholar
• Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell. 2003;3(5):431–7. doi:10.1016/S1535-6108(03)00113-2.
   PubMed Web of Science ®Google Scholar
• Boardman DA, Philippeos C, Fruhwirth GO, Ibrahim MAA, Hannen RF, Cooper D, Marelli-Berg FM, Watt FM, Lechler RI, Maher J, et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am J Transplant. 2017;17(4):931–43. doi:10.1111/ajt.14185.
   PubMed Web of Science ®Google Scholar
• Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45–56. doi:10.1038/s41586-019-1593-5.
   PubMed Web of Science ®Google Scholar
• Basar R, Daher M, Rezvani K. Next-generation cell therapies: the emerging role of CAR-NK cells. Hematology Am Soc Hematol Educ Program. 2020;2020(1):570–8. doi:10.1182/hematology.2020002547.
   PubMedGoogle Scholar
• Daher M, Rezvani K. Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-Engineered T cells in the race against cancer. Cancer Discov. 2021;11(1):45–58. doi:10.1158/2159-8290.CD-20-0556.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Fu Q, Zhang Y, Xu D, Wu Y, Qiu Q, Zhou W. CAR-based cell therapy: evaluation with bibliometrics and patent analysis. Hum Vaccin Immunother. 2021;17(11):4374–82. doi:10.1080/21645515.2021.1947100.
   PubMed Web of Science ®Google Scholar
• Ahmad A. CAR-T cell therapy. Int J Mol Sci. 2020;21(12):4303. doi:10.3390/ijms21124303.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Uddin S, Steinhoff M. CAR-T cell therapies: an overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-cell lymphomas. Int J Mol Sci. 2020;21(11):3906. doi:10.3390/ijms21113906.
   PubMed Web of Science ®Google Scholar
• Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, Huls H, Miller JC, Kebriaei P, Rabinovitch B, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119(24):5697–705. doi:10.1182/blood-2012-01-405365.
   PubMed Web of Science ®Google Scholar
• Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med. 2014;65(1):333–47. doi:10.1146/annurev-med-060512-150254.
   PubMedGoogle Scholar
• Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353(6295):179–84. doi:10.1126/science.aaf6756.
   PubMed Web of Science ®Google Scholar
• Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W, et al. Targeting cardiac fibrosis with engineered T cells. Nature. 2019;573(7774):430–3. doi:10.1038/s41586-019-1546-z.
   PubMed Web of Science ®Google Scholar
• Mao Y, Zhao C, Zheng P, Zhang X, Xu J. Current status and future development of anti-HIV chimeric antigen receptor T-cell therapy. Immunotherapy. 2021;13(2):177–84. doi:10.2217/imt-2020-0199.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Y, Tan X, Pan B, Ge J, Qi K, Cheng H, Cao J, Shi M, Yan Z, et al. Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection. Leukemia. 2020;34(10):2704–7. doi:10.1038/s41375-020-0936-4.
   PubMed Web of Science ®Google Scholar
• Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood. 2019;133(26):2800–2. doi:10.1182/blood.2019000888.
   PubMed Web of Science ®Google Scholar
• Ellegaard O, Wallin JA. The bibliometric analysis of scholarly production: how great is the impact? Scientometrics. 2015;105(3):1809–31. doi:10.1007/s11192-015-1645-z.
   PubMed Web of Science ®Google Scholar
• Lawson McLean A. Publication trends in transcranial magnetic stimulation: a 30-year panorama. Brain Stimul. 2019;12(3):619–27. doi:10.1016/j.brs.2019.01.002.
   PubMed Web of Science ®Google Scholar
• Zheng K, Wang X. Publications on the association between cognitive function and pain from 2000 to 2018: a bibliometric analysis using CiteSpace. Med Sci Monit. 2019;25:8940–51. doi:10.12659/MSM.917742.
   PubMed Web of Science ®Google Scholar
• Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci U S A. 2004;101 Suppl 1(Suppl 1):5303–10. doi:10.1073/pnas.0307513100.
   PubMed Web of Science ®Google Scholar
• Brookes BC. Bradford’s law and the bibliography of science. Nature. 1969;224(5223):953–6. doi:10.1038/224953a0.
   PubMed Web of Science ®Google Scholar
• Chen C. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci. 2006;57(3):359–77. doi:10.1002/asi.20317.
   Web of Science ®Google Scholar
• van Eck NJ, Waltman L. software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38. doi:10.1007/s11192-009-0146-3.
   PubMed Web of Science ®Google Scholar
• Ogunsakin RE, Ebenezer O, Ginindza TG. A bibliometric analysis of the literature on norovirus disease from 1991-2021. Int J Environ Res Public Health. 2022;19(5):2508. doi:10.3390/ijerph19052508.
   PubMed Web of Science ®Google Scholar
• Munim ZH, Dushenko M, Jimenez VJ, Shakil MH, Imset M. Big data and artificial intelligence in the maritime industry: a bibliometric review and future research directions. Marit Policy Manag. 2020;47(5):577–97. doi:10.1080/03088839.2020.1788731.
   Web of Science ®Google Scholar
• Chen C, Leydesdorff L. Patterns of connections and movements in dual-map overlays: a new method of publication portfolio analysis. J Assn Inf Sci Tec. 2014;65(2):334–51. doi:10.1002/asi.22968.
   Web of Science ®Google Scholar
• Schilling C, Stoeckli SJ, Haerle SK, Broglie MA, Huber GF, Sorensen JA, Bakholdt V, Krogdahl A, von Buchwald C, Bilde A, et al. Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. Eur J Cancer. 2015;51(18):2777–84. doi:10.1016/j.ejca.2015.08.023.
   PubMed Web of Science ®Google Scholar
• Den Toom IJ, Heuveling DA, Flach GB, van Weert S, Karagozoglu KH, van Schie A, Bloemena E, Leemans CR, de Bree R. Sentinel node biopsy for early-stage oral cavity cancer: the VU University Medical center experience: sentinel node biopsy for early oral cancer. Head Neck. 2015;37(4):573–8. doi:10.1002/hed.23632.
   PubMed Web of Science ®Google Scholar
• de Bree R, Takes RP, Castelijns JA, de Bree R, Medina JE, Stoeckli SJ, Mancuso AA, Hunt JL, Rodrigo JP, Triantafyllou A, et al. Advances in diagnostic modalities to detect occult lymph node metastases in head and neck squamous cell carcinoma: diagnostic modalities for detection of lymph node metastasis. Eisele DW, ed. Head Neck. 2015;37(12):1829–39. doi:10.1002/hed.23814.
   PubMed Web of Science ®Google Scholar
• Hirsch JE. an index to quantify an individual’s scientific research output. Proc Natl Acad Sci U S A. 2005;102(46):16569–72. doi:10.1073/pnas.0507655102.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17. doi:10.1056/NEJMoa1407222.
   PubMed Web of Science ®Google Scholar
• Ninkov A, Frank JR, Maggio LA. bibliometrics: methods for studying academic publishing. Perspect Med Educ. 2022;11(3):173–6. doi:10.1007/s40037-021-00695-4.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45–55. doi:10.1016/j.blre.2018.11.002.
   PubMed Web of Science ®Google Scholar
• West R, McIlwaine A. what do citation counts count for in the field of addiction? An empirical evaluation of citation counts and their link with peer ratings of quality: citations and quality. Addiction. 2002;97(5):501–4. doi:10.1046/j.1360-0443.2002.00104.x.
   PubMed Web of Science ®Google Scholar
• Radicchi F, Fortunato S, Castellano C. Universality of citation distributions: toward an objective measure of scientific impact. Proc Natl Acad Sci U S A. 2008;105(45):17268–72. doi:10.1073/pnas.0806977105.
   PubMed Web of Science ®Google Scholar
• Yoon SJ, Yoon DY, Ja Lim K, Moon JY, Hong SJ, Baek S, Yun EJ. The 100 top-cited articles focused on magnetic resonance: a bibliometric analysis. Acta radiol. 2019;60(6):710–5. doi:10.1177/0284185118795325.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. doi:10.1126/scitranslmed.3002842.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18. doi:10.1056/NEJMoa1215134.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298–310. doi:10.1016/S0140-6736(16)32407-2.
   PubMed Web of Science ®Google Scholar
• Vaqué JP, Martínez N, Batlle-López A, Perez C, Montes-Moreno S, Sanchez-Beato M, Piris MA. B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica. 2014;99(2):222–31. doi:10.3324/haematol.2013.096248.
   PubMed Web of Science ®Google Scholar
• International T-cell lymphoma project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. JCO. 2008;26(25):4124–30. doi:10.1200/JCO.2008.16.4558.
   Google Scholar
• Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524–39. doi:10.3324/haematol.2020.247031.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48. doi:10.1056/NEJMoa1709866.
   PubMed Web of Science ®Google Scholar
• Abramson JS. anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma. Transfus Med Rev. 2020;34(1):29–33. doi:10.1016/j.tmrv.2019.08.003.
   PubMed Web of Science ®Google Scholar
• Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, Guo X, Liu H, Ding N, Zhang T, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947–53. doi:10.1038/s41591-019-0421-7.
   PubMed Web of Science ®Google Scholar
• Danhof S, Hudecek M, Smith EL. CARs and other T cell therapies for MM: the clinical experience. Best Pract Res Clin Haematol. 2018;31(2):147–57. doi:10.1016/j.beha.2018.03.002.
   PubMed Web of Science ®Google Scholar
• Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, Daugaard M, Presseau J, Thavorn K, Hutton B, et al. Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev. 2019;33(2):98–110. doi:10.1016/j.tmrv.2019.01.005.
   PubMed Web of Science ®Google Scholar
• Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O’Connor RS, Hwang W-T, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563–71. doi:10.1038/s41591-018-0010-1.
   PubMed Web of Science ®Google Scholar
• Thudium Mueller K, Grupp SA, Maude SL, Levine JE, Pulsipher MA, Boyer MW, August KJ, Myers GD, Tam CS, Jaeger U, et al. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Adv. 2021;5(23):4980–91. doi:10.1182/bloodadvances.2020003844.
   PubMed Web of Science ®Google Scholar
• Liu Y, Bewersdorf JP, Stahl M, Zeidan AM. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: the dawn of a new era? Blood Rev. 2019;34:67–83. doi:10.1016/j.blre.2018.12.001.
   PubMed Web of Science ®Google Scholar
• Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, Andreadis C. Efficacy and safety of CD19 -directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET , ZUMA -1, and TRANSCEND trials. Am J Hematol. 2021;96(10):1295–312. doi:10.1002/ajh.26301.
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91–103. doi:10.1016/S1470-2045(21)00591-X.
   PubMed Web of Science ®Google Scholar
• Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z, Qian Q. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548–60. doi:10.7150/ijbs.34213.
   PubMed Web of Science ®Google Scholar
• Moghimi B, Muthugounder S, Jambon S, Tibbetts R, Hung L, Bassiri H, Hogarty MD, Barrett DM, Shimada H, Asgharzadeh S, et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun. 2021;12(1):511. doi:10.1038/s41467-020-20785-x.
   PubMed Web of Science ®Google Scholar
• Marofi F, Rahman HS, Achmad MH, Sergeevna KN, Suksatan W, Abdelbasset WK, Mikhailova MV, Shomali N, Yazdanifar M, Hassanzadeh A, et al. A deep insight into CAR-T cell therapy in non-Hodgkin lymphoma: application, opportunities, and future directions. Front Immunol. 2021;12:681984. doi:10.3389/fimmu.2021.681984.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhou Y, Zhang M, Ge W, Li Y, Yang L, Wei G, Han L, Wang H, Yu S, et al. CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2021;27(10):2764–72. doi:10.1158/1078-0432.CCR-20-3863.
   PubMed Web of Science ®Google Scholar
• Pavlasova G, Mraz M. the regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494–506. doi:10.3324/haematol.2019.243543.
   PubMed Web of Science ®Google Scholar
• Pierce JMR, Mehta A. Diagnostic, prognostic and therapeutic role of CD30 in lymphoma. Expert Rev Hematol. 2017;10(1):29–37. doi:10.1080/17474086.2017.1270202.
   PubMed Web of Science ®Google Scholar
• Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, Guo T, Kou H, Liu L, Tang L, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021;14(1):161. doi:10.1186/s13045-021-01170-7.
   PubMed Web of Science ®Google Scholar
• Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26(10):1569–75. doi:10.1038/s41591-020-1081-3.
   PubMed Web of Science ®Google Scholar
• Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, et al. CD22-Targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–8. doi:10.1038/nm.4441.
   PubMed Web of Science ®Google Scholar
• Jardin F. NFkB pathway and Hodgkin Lymphoma. Biomedicines. 2022;10(9):2153. doi:10.3390/biomedicines10092153.
   PubMed Web of Science ®Google Scholar
• Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14(1):73. doi:10.1186/s13045-021-01083-5.
   PubMed Web of Science ®Google Scholar
• Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):119. doi:10.1186/s13046-022-02327-z.
   PubMed Web of Science ®Google Scholar
• Lai J, Mardiana S, House IG, Sek K, Henderson MA, Giuffrida L, Chen AXY, Todd KL, Petley EV, Chan JD, et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat Immunol. 2020;21(8):914–26. doi:10.1038/s41590-020-0676-7.
   PubMed Web of Science ®Google Scholar
• Pensato U, Muccioli L, Cani I, Janigro D, Zinzani PL, Guarino M, Cortelli P, Bisulli F. Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy. Ann Clin Transl Neurol. 2021;8(4):968–79. doi:10.1002/acn3.51348.
   PubMed Web of Science ®Google Scholar
• Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020;146(5):940–8. doi:10.1016/j.jaci.2020.07.025.
   PubMed Web of Science ®Google Scholar
• Zhang C, Palashati H, Rong Z, Lin N, Shen L, Liu Y, Li S, Yu B, Yang W, Lu Z, et al. Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies. Mol Cancer. 2020;19(1):162. doi:10.1186/s12943-020-01282-7.
   PubMed Web of Science ®Google Scholar
• Liu G, Rui W, Zhao X, Lin X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol. 2021;18(5):1085–95. doi:10.1038/s41423-021-00655-2.
   PubMed Web of Science ®Google Scholar
• Zebley CC, Youngblood B. Mechanisms of T cell exhaustion guiding next-generation immunotherapy. Trends Cancer. 2022;8(9):726–34. doi:10.1016/j.trecan.2022.04.004.
   PubMed Web of Science ®Google Scholar
• Hu Y, Li J, Ni F, Yang Z, Gui X, Bao Z, Zhao H, Wei G, Wang Y, Zhang M, et al. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nat Commun. 2022;13(1):5313. doi:10.1038/s41467-022-32960-3.
   PubMed Web of Science ®Google Scholar
• Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022;28(4):713–23. doi:10.1038/s41591-022-01702-9.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, et al. HER2-Specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma. JAMA Oncol. 2017;3(8):1094–101. doi:10.1001/jamaoncol.2017.0184.
   PubMed Web of Science ®Google Scholar
• Hu Z, Zheng X, Jiao D, Zhou Y, Sun R, Wang B, Tian Z, Wei H. LunX-CAR T cells as a targeted therapy for non-small cell lung cancer. Mol Ther Oncolytics. 2020;17:361–70. doi:10.1016/j.omto.2020.04.008.
   PubMed Web of Science ®Google Scholar
• Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, Shaik RS, Nguyen TP, Wu M-F, Bulsara S, et al. Glypican-3–specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer Immunol Res. 2020;8(3):309–20. doi:10.1158/2326-6066.CIR-19-0293.
   PubMed Web of Science ®Google Scholar
• Jiang H, Shi Z, Wang P, Wang C, Yang L, Du G, Zhang H, Shi B, Jia J, Li Q, et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. JNCI J Nat Cancer Inst. 2019;111(4):409–18. doi:10.1093/jnci/djy134.
   PubMedGoogle Scholar
• Li H, Ding J, Lu M, Liu H, Miao Y, Li L, Wang G, Zheng J, Pei D, Zhang Q, et al. CAIX-specific CAR-T cells and sunitinib show synergistic effects against metastatic renal cancer models. J Immunother. 2020;43(1):16–28. doi:10.1097/CJI.0000000000000301.
   PubMed Web of Science ®Google Scholar
• Gorchakov AA, Kulemzin SV, Kochneva GV, Taranin AV. challenges and prospects of chimeric antigen receptor T-cell therapy for metastatic prostate cancer. Eur Urol. 2020;77(3):299–308. doi:10.1016/j.eururo.2019.08.014.
   PubMed Web of Science ®Google Scholar
• Safarzadeh Kozani P, Safarzadeh Kozani P, Ahmadi Najafabadi M, Yousefi F, Mirarefin SMJ, Rahbarizadeh F. recent advances in solid tumor CAR-T cell therapy: driving tumor cells from hero to zero? Front Immunol. 2022;13:795164. doi:10.3389/fimmu.2022.795164.
   PubMed Web of Science ®Google Scholar
• Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M, Shomali N, Chartrand MS, Pathak Y, Jarahian M, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12(1):81. doi:10.1186/s13287-020-02128-1.
   PubMed Web of Science ®Google Scholar
• Lancet Oncology T. The lancet oncology. CAR T-cell therapy for solid tumours. Lancet Oncol. 2021;22(7):893. doi:10.1016/S1470-2045(21)00353-3.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ping J, Huang Z, Zhang X, Zhou J, Wang G, Liu S, Ma J. CAR-T cell therapy in cancer: tribulations and road ahead. J Immunol Res. 2020;2020:1–11. doi:10.1155/2020/1924379.
   Web of Science ®Google Scholar